The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 29, 2021

Filed:

May. 05, 2017
Applicant:

Maxwell Biotech Group Ltd., Moscow, RU;

Inventors:

Ekaterina Alekseevna Ivanova, Moscow, RU;

Alexander Karpeisky, Lafayette, CO (US);

Shawn P. Zinnen, Denver, CO (US);

Lisa Lynn Caralli, Del Mar, CA (US);

Rina Diana Fong, San Diego, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); A01N 43/04 (2006.01); A61K 31/7068 (2006.01); A61K 47/02 (2006.01); A61P 35/00 (2006.01); A61K 31/663 (2006.01); A61P 19/00 (2006.01); A61K 9/19 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/26 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7068 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/663 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61P 19/00 (2018.01); A61P 35/00 (2018.01);
Abstract

This invention relates to oncology, and specifically to a novel medicinal drug and a method for treating bone lesions caused by malignant neoplasms. A medicinal drug that represents a lyophilisate for solution for parenteral administration, including the following components: pharmaceutically acceptable salt of the divalent metal and 1-((((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidine-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy))(hydroxy)phosphoryloxy)(hydroxy)phosphoryl)-1-hydroxyethylphosphonic acid or pharmaceutically acceptable salt hereof with a molar ratio of the components ranging from 1:1 to 20:1 is proposed for this purpose. The treatment method includes the drug solution administration according to the invention in the form of intravenous drop infusions in a dose ranging from 0.01 to 5 mg/kg of the active component per 1 kg of the patient's weight in the form of intravenous drop infusions. The treatment with the medicinal drug according to the invention allows to reduce the metabolic activity of bone lesions caused by malignant tumours up to 100%.


Find Patent Forward Citations

Loading…